- Home
- ACRV vs GOSS Comparison
ACRV vs GOSS Comparison
Compare ACRV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- GOSS
- Stock Information
- Founded
- ACRV 2018
- GOSS 2015
- Country
- ACRV United States
- GOSS United States
- Employees
- ACRV N/A
- GOSS N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- GOSS Health Care
- Exchange
- ACRV Nasdaq
- GOSS Nasdaq
- Market Cap
- ACRV 203.9M
- GOSS 212.9M
- IPO Year
- ACRV 2022
- GOSS 2019
- Fundamental
- Price
- ACRV $6.60
- GOSS $0.81
- Analyst Decision
- ACRV Strong Buy
- GOSS Strong Buy
- Analyst Count
- ACRV 5
- GOSS 5
- Target Price
- ACRV $22.40
- GOSS $9.20
- AVG Volume (30 Days)
- ACRV 63.5K
- GOSS 2.3M
- Earning Date
- ACRV 11-13-2024
- GOSS 11-07-2024
- Dividend Yield
- ACRV N/A
- GOSS N/A
- EPS Growth
- ACRV N/A
- GOSS N/A
- EPS
- ACRV N/A
- GOSS N/A
- Revenue
- ACRV N/A
- GOSS $105,322,000.00
- Revenue This Year
- ACRV N/A
- GOSS N/A
- Revenue Next Year
- ACRV N/A
- GOSS N/A
- P/E Ratio
- ACRV N/A
- GOSS N/A
- Revenue Growth
- ACRV N/A
- GOSS N/A
- 52 Week Low
- ACRV $3.19
- GOSS $0.50
- 52 Week High
- ACRV $11.90
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- ACRV 42.20
- GOSS 49.87
- Support Level
- ACRV $6.56
- GOSS $0.76
- Resistance Level
- ACRV $7.45
- GOSS $0.88
- Average True Range (ATR)
- ACRV 0.47
- GOSS 0.08
- MACD
- ACRV -0.00
- GOSS 0.01
- Stochastic Oscillator
- ACRV 28.12
- GOSS 30.48
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.